| Medical and Health Sciences | Lifetime | 168 | SE 3 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 39 | SE 2 | 99.99 |
| Biological Sciences | 2021-2025 | 348 | SE 1 | 99.64 |
| Medical Physiology | Lifetime | 11 | SE 2 | 99.98 |
| Psychiatry and Mental health | Lifetime | 43 | SE 4 | 99.87 |
| Clinical Neurology | Lifetime | 55 | SE 1 | 99.79 |
| Neuroscience of Neurology | Lifetime | 83 | SE 2 | 99.30 |
| Epidemiology | Lifetime | 537 | SE 4 | 99.34 |
| Pathology and Forensic Medicine | Lifetime | 450 | SE 10 | 98.15 |
| Cellular and Molecular Neuroscience | Lifetime | 707 | SE 29 | 96.94 |
| Rheumatology | Lifetime | 700 | SE 15 | 96.46 |
| Critical Care and Intensive Care Medicine | Lifetime | 233 | SE 1 | 95.40 |
| Emergency Medicine | Lifetime | 529 | SE 12 | 95.09 |
| Virology | Lifetime | 475 | SE 4 | 84.96 |
| Developmental Neuroscience | Lifetime | 399 | SE 13 | 83.50 |
| Biological Psychiatry | Lifetime | 244 | SE 6 | 80.63 |
| Medical Physiology | 2021-2025 | 3 | SE 2 | 99.96 |
| Psychiatry and Mental health | 2021-2025 | 6 | SE 2 | 99.94 |
| Clinical Neurology | 2021-2025 | 10 | SE 1 | 99.67 |
| Cellular and Molecular Neuroscience | 2021-2025 | 13 | SE 1 | 98.68 |
| Epidemiology | 2021-2025 | 224 | SE 4 | 98.35 |
| Neuroscience of Neurology | 2021-2025 | 56 | SE 2 | 96.85 |
| Molecular Biology | 2021-2025 | 508 | SE 3 | 97.39 |
| Critical Care and Intensive Care Medicine | 2021-2025 | 41 | SE 1 | 97.10 |
| Cognitive Neuroscience | 2021-2025 | 345 | SE 2 | 93.74 |
| Pathology and Forensic Medicine | 2021-2025 | 252 | SE 4 | 92.36 |
| Public, Environmental and Occupational Health | 2021-2025 | 809 | SE 12 | 91.91 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 762 | SE 11 | 90.16 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 512 | SE 5 | 89.37 |
| Cell Biology | 2021-2025 | 151 | SE 1 | 87.67 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 462 | SE 10 | 88.76 |
| Emergency Medicine | 2021-2025 | 202 | SE 4 | 88.42 |
| Genetics | 2021-2025 | 513 | SE 13 | 85.52 |
| Rheumatology | 2021-2025 | 371 | SE 12 | 85.32 |
| Virology | 2021-2025 | 119 | SE 1 | 77.81 |
| Biological Psychiatry | 2021-2025 | 74 | SE 2 | 76.57 |
| Nephrology | 2021-2025 | 311 | SE 8 | 74.78 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 868 | SE 16 | 74.84 |
| Immunology | 2021-2025 | 864 | SE 5 | 69.38 |
| S100 Proteins and Annexins | Lifetime | 3 | SE 2 | 99.82 |
| Alzheimer's disease research and treatments | Lifetime | 11 | SE 2 | 99.98 |
| Dementia and Cognitive Impairment Research | Lifetime | 9 | SE 2 | 99.97 |
| Traumatic Brain Injury and Neurovascular Disturbances | Lifetime | 25 | SE 2 | 99.86 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 27 | SE 1 | 99.87 |
| Traumatic Brain Injury Research | Lifetime | 17 | SE 1 | 99.64 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 24 | SE 2 | 99.77 |
| Folate and B Vitamins Research | Lifetime | 55 | SE 2 | 98.94 |
| Cerebrospinal fluid and hydrocephalus | Lifetime | 45 | SE 1 | 99.22 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 79 | SE 2 | 99.31 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 46 | SE 5 | 99.46 |
| Cardiac Arrest and Resuscitation | Lifetime | 152 | SE 5 | 99.44 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 110 | SE 2 | 99.56 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 74 | SE 5 | 99.18 |
| Amyotrophic Lateral Sclerosis Research | Lifetime | 53 | SE 2 | 99.22 |
| Long-Term Effects of COVID-19 | Lifetime | 179 | SE 1 | 98.26 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 68 | SE 3 | 98.85 |
| Health, Environment, Cognitive Aging | Lifetime | 59 | SE 3 | 98.82 |
| Advanced Neuroimaging Techniques and Applications | Lifetime | 209 | SE 4 | 98.98 |
| Computational Drug Discovery Methods | Lifetime | 403 | SE 10 | 98.10 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 411 | SE 12 | 97.83 |
| Multiple Sclerosis Research Studies | Lifetime | 213 | SE 7 | 98.52 |
| Neurological diseases and metabolism | Lifetime | 113 | SE 2 | 98.46 |
| Functional Brain Connectivity Studies | Lifetime | 516 | SE 7 | 98.71 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 405 | SE 9 | 98.25 |
| Inflammation biomarkers and pathways | Lifetime | 41 | SE 1 | 96.94 |
| Neurological and metabolic disorders | Lifetime | 160 | SE 4 | 96.60 |
| Prion Diseases and Protein Misfolding | Lifetime | 158 | SE 4 | 97.40 |
| Anesthesia and Neurotoxicity Research | Lifetime | 610 | SE 20 | 96.52 |
| Tryptophan and brain disorders | Lifetime | 664 | SE 13 | 97.07 |
| Skin and Cellular Biology Research | Lifetime | 264 | SE 3 | 96.57 |
| Genetic Neurodegenerative Diseases | Lifetime | 698 | SE 5 | 96.46 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 503 | SE 5 | 96.37 |
| Bioinformatics and Genomic Networks | Lifetime | 916 | SE 9 | 94.56 |
| Nuclear Receptors and Signaling | Lifetime | 392 | SE 10 | 94.83 |
| RNA regulation and disease | Lifetime | 798 | SE 6 | 94.32 |
| Peripheral Neuropathies and Disorders | Lifetime | 699 | SE 13 | 95.18 |
| Neurogenetic and Muscular Disorders Research | Lifetime | 798 | SE 13 | 93.91 |
| Advanced Proteomics Techniques and Applications | Lifetime | 866 | SE 25 | 93.38 |
| Cancer-related cognitive impairment studies | Lifetime | 391 | SE 6 | 92.38 |
| HIV-related health complications and treatments | Lifetime | 973 | SE 6 | 93.59 |
| Hereditary Neurological Disorders | Lifetime | 626 | SE 5 | 91.81 |
| Studies on Chitinases and Chitosanases | Lifetime | 417 | SE 4 | 89.23 |
| Cerebrovascular and genetic disorders | Lifetime | 391 | SE 16 | 87.18 |
| Ginkgo biloba and Cashew Applications | Lifetime | 540 | SE 4 | 83.32 |
| GDF15 and Related Biomarkers | Lifetime | 540 | SE 22 | 81.21 |
| Down syndrome and intellectual disability research | Lifetime | 679 | SE 11 | 81.04 |
| Biological Research and Disease Studies | Lifetime | 88 | SE 2 | 72.65 |
| Clusterin in disease pathology | Lifetime | 830 | SE 22 | 47.53 |
| Alzheimer's disease research and treatments | 2021-2025 | 3 | SE 2 | 99.99 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 3 | SE 2 | 99.98 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 13 | SE 1 | 99.64 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 17 | SE 2 | 99.36 |
| Cerebrospinal fluid and hydrocephalus | 2021-2025 | 7 | SE 1 | 99.02 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 19 | SE 1 | 99.29 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 9 | SE 1 | 99.18 |
| Traumatic Brain Injury Research | 2021-2025 | 19 | SE 1 | 98.94 |
| Long-Term Effects of COVID-19 | 2021-2025 | 145 | SE 3 | 98.20 |
| S100 Proteins and Annexins | 2021-2025 | 11 | SE 2 | 97.00 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 29 | SE 5 | 96.72 |
| Skin and Cellular Biology Research | 2021-2025 | 10 | SE 1 | 96.72 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 137 | SE 4 | 97.91 |
| Neurological diseases and metabolism | 2021-2025 | 20 | SE 1 | 96.55 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 51 | SE 1 | 95.49 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 241 | SE 12 | 97.33 |
| Functional Brain Connectivity Studies | 2021-2025 | 319 | SE 6 | 97.00 |
| Neuroscience and Neuropharmacology Research | 2021-2025 | 214 | SE 2 | 95.85 |
| Folate and B Vitamins Research | 2021-2025 | 52 | SE 3 | 92.72 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 220 | SE 7 | 94.65 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 175 | SE 4 | 96.72 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 111 | SE 3 | 95.63 |
| Cancer-related cognitive impairment studies | 2021-2025 | 68 | SE 3 | 93.40 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 69 | SE 2 | 91.53 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 125 | SE 3 | 95.31 |
| Epilepsy research and treatment | 2021-2025 | 251 | SE 4 | 95.48 |
| Mitochondrial Function and Pathology | 2021-2025 | 342 | SE 6 | 92.44 |
| Tryptophan and brain disorders | 2021-2025 | 422 | SE 4 | 92.44 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 231 | SE 2 | 92.38 |
| Prion Diseases and Protein Misfolding | 2021-2025 | 52 | SE 1 | 91.33 |
| Bioinformatics and Genomic Networks | 2021-2025 | 250 | SE 3 | 90.25 |
| Multiple Sclerosis Research Studies | 2021-2025 | 308 | SE 10 | 95.04 |
| Health, Environment, Cognitive Aging | 2021-2025 | 226 | SE 6 | 91.25 |
| Bipolar Disorder and Treatment | 2021-2025 | 288 | SE 8 | 92.19 |
| Genetic Associations and Epidemiology | 2021-2025 | 614 | SE 11 | 89.72 |
| Advanced Neuroimaging Techniques and Applications | 2021-2025 | 787 | SE 13 | 89.37 |
| RNA regulation and disease | 2021-2025 | 263 | SE 1 | 84.99 |
| Neurological and metabolic disorders | 2021-2025 | 58 | SE 2 | 84.85 |
| Neurogenetic and Muscular Disorders Research | 2021-2025 | 390 | SE 3 | 88.35 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 419 | SE 5 | 89.60 |
| Spinal Dysraphism and Malformations | 2021-2025 | 162 | SE 6 | 85.35 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 325 | SE 4 | 84.98 |
| Hereditary Neurological Disorders | 2021-2025 | 155 | SE 1 | 86.19 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 550 | SE 3 | 86.18 |
| Neurogenesis and neuroplasticity mechanisms | 2021-2025 | 332 | SE 4 | 83.31 |
| HIV Research and Treatment | 2021-2025 | 984 | SE 8 | 85.90 |
| Anesthesia and Sedative Agents | 2021-2025 | 646 | SE 4 | 80.54 |
| Polyomavirus and related diseases | 2021-2025 | 487 | SE 12 | 80.82 |
| Genetic Syndromes and Imprinting | 2021-2025 | 359 | SE 4 | 75.61 |
| HIV-related health complications and treatments | 2021-2025 | 699 | SE 7 | 81.10 |
| Down syndrome and intellectual disability research | 2021-2025 | 181 | SE 1 | 81.03 |
| GDF15 and Related Biomarkers | 2021-2025 | 184 | SE 10 | 75.03 |
| Neonatal and fetal brain pathology | 2021-2025 | 994 | SE 27 | 79.65 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 207 | SE 3 | 71.57 |
| Advanced Proteomics Techniques and Applications | 2021-2025 | 567 | SE 16 | 77.92 |
| Cellular transport and secretion | 2021-2025 | 760 | SE 4 | 73.35 |
| Aging, Elder Care, and Social Issues | 2021-2025 | 290 | SE 3 | 73.77 |
| Memory and Neural Mechanisms | 2021-2025 | 937 | SE 7 | 73.44 |
| Syphilis Diagnosis and Treatment | 2021-2025 | 453 | SE 5 | 73.83 |
| Cerebrovascular and genetic disorders | 2021-2025 | 198 | SE 3 | 69.60 |
| Fetal and Pediatric Neurological Disorders | 2021-2025 | 947 | SE 12 | 69.54 |
| Nuclear Receptors and Signaling | 2021-2025 | 363 | SE 3 | 66.84 |
| Neurological Complications and Syndromes | 2021-2025 | 415 | SE 5 | 66.26 |
| Inflammation biomarkers and pathways | 2021-2025 | 156 | SE 4 | 65.64 |
| Clusterin in disease pathology | 2021-2025 | 90 | SE 4 | 51.13 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 669 | SE 5 | 42.27 |
| Biotin and Related Studies | 2021-2025 | 507 | SE 4 | 22.80 |
| 14-3-3 protein interactions | 2021-2025 | 290 | SE 1 | 18.12 |
| Cognitive Functions and Memory | 2021-2025 | 947 | SE 17 | 18.49 |